A Dose-Escalation/ Dose-Expansion Study of SY-3505 in Patients With ALK-positive Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label and multi-center study of SY-3505, a third-generation ALK TKI,
in patients with ALK-positive non-small cell lung cancer (ALK-positive NSCLC). This study has
two phases: dose-escalation phase and dose-expansion phase.